6-Dimethylamino-2-methyl-pyridin-3-carbonitril

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-Dimethylamino-2-methyl-pyridin-3-carbonitril
• 英文别名: 6-(dimethylamino)-2-methylnicotinonitrile；6-dimethylamino-2-methyl-nicotinonitrile；6-(dimethylamino)-2-methylpyridine-3-carbonitrile
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: BCTSBUWVQZRNFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Dimethylamino-2-methyl-pyridin-3-carbonitril 在 镍 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以to provide the product (180 mg, 91%), which的产率得到5-(aminomethyl)-N,N,6-trimethylpyridin-2-amine
  参考文献：
  名称：

  THERAPEUTIC INHIBITORY COMPOUNDS

  摘要：

  本文提供了一些杂环衍生物化合物和含有这些化合物的药物组合物，这些化合物对抑制血浆卡利肌酶具有用处。此外，这些化合物和组合物对于治疗已被认为与血浆卡利肌酶抑制有关的疾病，如血管性水肿等，具有用处。

  公开号：

  US20160200704A1
• 作为产物：
  描述：

  3-氨基巴豆腈 、 3,3,3-tris(dimethylamino)propyne 以 四氢呋喃 为溶剂， 反应 43.0h， 以55%的产率得到6-Dimethylamino-2-methyl-pyridin-3-carbonitril
  参考文献：
  名称：

  Orthoamide. LI. Push-Pull-Butadiene und Heterocyclen aus CH2-aciden Verbindungen und Orthoamiden von Alkincarbons�uren

  摘要：

  The acetylides 4b, 4f react with N,N,N',N',N ",N "-hexamethylguanidiniumchloride (5) to give the orthoamides 6b, 6f, resp. From CH2-acidic compounds and the orthoamides 6a, c, e can be obtained the push-pull-substituted butadienes 8a-8aj. The 2,3,5-trimethyl-thiadiazolium salt 9 does not condense with 6e, as other CH2-acidic compounds do, instead the vinylogous guanidinium salt 10a is produced. On healing, the ketenaminals 8d, aa cyclize to give the pyridone-carbonitriles 11a, b, resp. From di-amino-coumarins 12 and the ortho-carboxylic acid amideacetals 13a, b and the ketenaminal 16 resp., the amidines 14a-c and the heterocyclic compounds 15a-c resp., are formed. The enamines 17a-c, 19a, b react with the orthoamides 6a-f to give the pyridine derivatives 18a-l, 20a-h and 21a, b, resp. Analogously, from 6-amino-uracil 22 and 6a, b, e, fare formed the pure 7-dimethylaminopyrido[2,3-d] pyrimidines 23a, b or mixtures of compounds 23c, d and the isomeric 4-dimethylamino-pyrido[2,3d]pyrimidines 24a, b resp., which can be separated via their salts 25a,b/26a,b. The heterocyclic compounds 30a-d, 32a,16 can be prepared from the pyrazole derivatives 28, 31 resp. and the orthoamides 6a-f.

  DOI：

  10.1002/prac.19983400503

文献信息

• Therapeutic inhibitory compounds
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US10023557B2

  公开（公告）日：2018-07-17

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供的杂环衍生物化合物和药物组合物包含所述化合物，可用于抑制血浆卡利克林。此外，所述化合物和组合物还可用于治疗与血浆卡利克酶抑制作用有关的疾病，如血管性水肿等。
• THERAPEUTIC INHIBITORY COMPOUDS
  申请人：Lifesci Pharmaceuticals, Inc.

  公开号：EP3316884A1

  公开（公告）日：2018-05-09
• Androgen receptor modulators
  申请人：Hu Lain-Yen

  公开号：US20070129409A1

  公开（公告）日：2007-06-07

  The present invention is directed to a new class of 5-cyano-2-amino pyridines and to their use as androgen receptor modulators. A further aspect of the invention is directed to a new animal model for finding compounds capable of alleviating androgenic alopecia.
• US9611252B2
  申请人：——

  公开号：US9611252B2

  公开（公告）日：2017-04-04
• [EN] THERAPEUTIC INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2016011209A1

  公开（公告）日：2016-01-21

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.